Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: A real-world experience

Gut

Volumn 66, Issue 11, 2017, Pages 2008-2012

  El Khayat, Hisham R ^a   Fouad, Yasser M ^b   Maher, Mohsen ^c   El Amin, Hussain ^d   Muhammed, Hala ^b  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b MINIA UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d ASSIUT UNIVERSITY   (Egypt)

Author keywords

CHRONIC HEPATITIS; CIRRHOSIS; HCV

Indexed keywords

INTERFERON; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EGYPTIAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERBILIRUBINEMIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; SCORING SYSTEM; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; EGYPT; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84981495326     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312012     Document Type: Article

References (19)

1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-42.
3. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomized study. Lancet 2014;384:1756-65.
4. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45.
5. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
6. Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol 2015;62:286-93.
7. Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014;147:132-42.
8. Kwo P, Gitlin N, Nahass R, et al. Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. Hepatology 2016;64:370-80.
9. Clark V, Nelson DR. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int 2012;32(Suppl 1):103-7.
10. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection Gastroenterology 2016;150:419-29.
11. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016;64:360-9.
12. Wu CJ, Roytman MM, Hong LK, et al. Real-world experience with sofosbuvir-based regimens for chronic hepatitis C, including patients with factors previously associated with inferior treatment response. Hawaii J Med Public Health 2015;74: (Suppl 2):3-7.
13. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponder to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomized study. Lancet 2014;384:1756-65.
14. Yee BE, Nghia NH, Jin M, et al. Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical Trials Brittany. BMJ Open Gastroenterol 2016;3:e000056.
15. Manns MP, McCone J, Davis MN, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: A combined analysis of 3 phase 2/3 clinical trials. Liver Int 2014;34:707-19.
16. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol 2015;62:S270.
17. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY Trial. Boston, MA: AASLD, 2014.
18. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype1 infection. N Engl J Med 2014;370:1483-93.
19. Bourlire M, Sulkowski MS, Omata M, et al. An integrated safety and efficacy analysis of 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 2014;60:239.